津力达颗粒联合聚乙二醇洛塞那肽对气阴两虚型糖尿病肾病患者内皮功能及AGEs水平的影响

Effects of Jinlida Granule combined with polyethylene glycol loxenatide on endothelial function and AGEs levels in patients with diabetic kidney disease of qi and yin deficiency type

关键词:  津力达颗粒  聚乙二醇洛塞那肽  糖尿病肾病  内皮功能

Key words:  Jinlida Granule  polyethylene glycol loxenatide  diabetic kidney disease  endothelial function

摘要:

[目的] 探究津力达颗粒联合聚乙二醇洛塞那肽对气阴两虚型糖尿病肾病（DKD）患者内皮功能及晚期糖基化终末产物（AGEs）水平的影响。[方法] 选取河北省沧州中西医结合医院105例气阴两虚DKD患者按随机数字表法随机分为对照组52例和治疗组53例（2024年1月—2025年1月）。两组患者均先给予常规治疗，对照组给予聚乙二醇洛塞那肽治疗，治疗组在对照组处理基础上给予津力达颗粒治疗。比较两组的内皮功能、AGEs、人单核细胞趋化蛋白1（MCP-1）、中医证候积分、血糖、肾功能情况。[结果] 治疗后，两组一氧化氮（NO）升高，治疗组更高（P＜0.05）；两组内皮素-1（ET-1），AGEs，MCP-1，中医证候积分中头晕目眩、神疲乏力、咽干口燥评分，空腹血糖（FPG），餐后2 h血糖（2 h PG），尿素氮（BUN），血肌酐（Scr），24 h尿蛋白定量降低，治疗组更低（P＜0.05）。[结论] 津力达颗粒联合聚乙二醇洛塞那肽治疗气阴两虚型DKD通过改善血管舒张功能，可以降低血管阻力，改善血管功能；也可以改善肾脏微循环，减轻肾脏炎症反应，减轻肾脏损伤。

Abstract:

[Objective] To explore the impacts of joint of Jinlida Granule and polyethylene glycol loxenatide on endothelial function and advanced glycation end products （AGEs） in patients with diabetic kidney disease （DKD） with qi and yin deficiency symptom. [Methods] Totally 105 patients with qi and yin deficiency type DKD in Cangzhou Integrated Traditional and Western Medicine Hospital were assigned into control group of 52 cases and treatment group of 53 cases randomly （from January 2024 to January 2025）. Both groups were given regular treatment，while the control group adopted polyethylene glycol loxenatide，and the treatment group adopted Jinlida Granule on the top of control group. Two groups were compared in terms of endothelial function，AGEs，human monocyte chemoattractant protein-1 （MCP-1），Chinese medicine syndrome score，blood glucose，and renal function. [Results] After treatment，the nitric oxide （NO） increased in both groups，with the treatment group having a higher level （P＜0.05）. The levels of endothelin-1 （ET-1），AGEs，MCP-1，traditional Chinese medicine syndrome scores of dizziness，fatigue，dry throat and dry mouth，fasting plasma glucose （FPG），2 h postprandial blood glucose （2 h PG），blood urea nitrogen （BUN），serum creatinine （Scr） and 24-hour urinary protein quantificationwere decreased in the two groups，and the treatment group was lower than the control group （P＜0.05）. [Conclusion] The joint of Jinlida Granule and polyethylene glycol loxenatide in treating qi and yin deficiency type DKD can improve vascular diastolic function，reduce vascular resistance，and enhance vascular function. It can also improve renal microcirculation，reduce renal inflammatory response，and alleviate renal damage.